Xpovio (Selinexor)
Brand Names: Xpovio
Methodology & AI Transparency ⓘ
Xpovio (Selinexor) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2026-05-12 designates Xpovio (NDC 72237-101, 72237-106, registered by Karyopharm Therapeutics Inc.) as a prescription brand-name nuclear export inhibitor formulation of Selinexor.
- 2 Real-world patient consensus: Commercial Xpovio monograph (40 mg/1 Tablet, Film Coated) cross-indexed with generic Selinexor for therapeutic equivalence review.
- 3 Typical cash cost range: Public pharmacy ledger: $40.90 low cash benchmark vs. $108.38 chain retail average ($0.4500/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Xpovio (Selinexor) include nausea (11.3%), diarrhea (8.6%), fatigue (9%).
Ask our AI Specialists anything about Xpovio (Selinexor)
Xpovio (Selinexor) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2026-05-12 designates Xpovio (NDC 72237-101, 72237-106, registered by Karyopharm Therapeutics Inc.) as a prescription brand-name nuclear export inhibitor formulation of Selinexor. Supplied across 40 mg/1 Tablet, Film Coated; 60 mg/1 Tablet, Film Coated, Xpovio is utilized in 1 Indications and usage xpovio: is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone.
Clinical pharmacology for Xpovio is driven by Selinexor acting within nuclear export inhibitor signaling cascades with class-characteristic hepatorenal disposition. Distributed across 40 mg/1 Tablet, Film Coated; 60 mg/1 Tablet, Film Coated (NDC 72237-101, 72237-106; registered by Karyopharm Therapeutics Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $40.90 to $108.38.
Following administration (40 mg/1 Tablet, Film Coated), Xpovio (Selinexor) achieves Consistent 62%–74% gastrointestinal absorption profile for Xpovio (Selinexor) bioavailability and cmax attained 2–3 hours post-administration of xpovio (selinexor) onset, governed by a Elimination kinetics span 8 to 18 hours per Xpovio (Selinexor) clinical pharmacology terminal half-life through systemic clearance of xpovio (selinexor) integrates hepatic phase ii conjugation with renal filtration.
Before initiating Xpovio (Selinexor) at 40 mg/1 Tablet, Film Coated, clinical safety checklists rule out history of severe allergic sensitivity to xpovio (selinexor) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-05-12 selinexor labeling. Logged tolerability patterns center on nausea (11.3% of reports), fatigue (9% of reports), diarrhea (8.6% of reports).
Verify medication reconciliation lists so Xpovio (Selinexor) is not inadvertently duplicated with another nuclear export inhibitor.
Botanical enzyme modulators may alter oral first-pass exposure of Xpovio (Selinexor); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Xpovio (Selinexor) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-05-12 Selinexor labeling
Logged Side-Effect Incidence (11 Reports)
Xpovio (Selinexor) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Xpovio (Selinexor))
Human clinical trial evidence for Xpovio (Selinexor) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Xpovio (Selinexor) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4500/unit (~$13.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $108.38 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $40.90 / mo | View logs ↓ |
Xpovio (Selinexor) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Xpovio (Selinexor) RxNorm Concept ID | 2178402 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $108.38 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $40.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Xpovio (Selinexor) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Xpovio (Selinexor): FDA labeling (2026-05-12, NDC 72237-101), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Xpovio (Selinexor) community threads and patient logs by age, biological sex, dosage, and treatment duration.